NICE issues final rebuff to Novartis' Afinitor

Novartis' battle to win over the UK's cost-effectiveness watchdog to its kidney cancer treatment Afinitor has hit a dead end, as the National Institute for Health and Clinical Excellence determined the drug is too expensive for that use. Report

Suggested Articles

While the failure might be a missed chance at revenue, it shouldn’t hurt Ibrance’s ability to rack up sales in the metastatic setting, one exec says.

Patients receiving Bavencio actually did worse than those who got placebo, increasing the risk of death by 31%.

Seattle Genetics and Astellas’ newcomer Padcev now has what every cancer drugmaker is looking for: Randomized trial data showing it can extend lives.